Avenue Therapeutics Performance
| ATXIDelisted Stock | USD 0.36 0.02 5.26% |
The firm shows a Beta (market volatility) of 1.62, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Avenue Therapeutics will likely underperform. At this point, Avenue Therapeutics has a negative expected return of -2.13%. Please make sure to confirm Avenue Therapeutics' total risk alpha and the relationship between the skewness and relative strength index , to decide if Avenue Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Avenue Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite inconsistent performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
| Begin Period Cash Flow | 6.7 M | |
| Free Cash Flow | -12.5 M |
Avenue |
Avenue Therapeutics Relative Risk vs. Return Landscape
If you would invest 180.00 in Avenue Therapeutics on December 23, 2024 and sell it today you would lose (144.00) from holding Avenue Therapeutics or give up 80.0% of portfolio value over 90 days. Avenue Therapeutics is currently does not generate positive expected returns and assumes 8.4799% risk (volatility on return distribution) over the 90 days horizon. In different words, 75% of pink sheets are less volatile than Avenue, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Avenue Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Avenue Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Avenue Therapeutics, and traders can use it to determine the average amount a Avenue Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2516
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ATXI |
Estimated Market Risk
| 8.48 actual daily | 75 75% of assets are less volatile |
Expected Return
| -2.13 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.25 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Avenue Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Avenue Therapeutics by adding Avenue Therapeutics to a well-diversified portfolio.
Avenue Therapeutics Fundamentals Growth
Avenue Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Avenue Therapeutics, and Avenue Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Avenue Pink Sheet performance.
| Return On Equity | -5.35 | ||||
| Return On Asset | -4.72 | ||||
| Current Valuation | (1.73 M) | ||||
| Shares Outstanding | 2.05 M | ||||
| Price To Earning | (10.52) X | ||||
| Price To Book | 0.33 X | ||||
| EBITDA | 4.05 M | ||||
| Cash And Equivalents | 890 K | ||||
| Cash Per Share | 0.60 X | ||||
| Total Debt | 1.2 M | ||||
| Debt To Equity | 23.40 % | ||||
| Book Value Per Share | 1.63 X | ||||
| Cash Flow From Operations | (9.45 M) | ||||
| Earnings Per Share | 24.78 X | ||||
| Total Asset | 1.85 M | ||||
| Retained Earnings | (90.93 M) | ||||
| Current Asset | 111.05 K | ||||
| Current Liabilities | 4.67 M | ||||
About Avenue Therapeutics Performance
By evaluating Avenue Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Avenue Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Avenue Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Avenue Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acuteintensive care hospital setting. The company was incorporated in 2015 and is based in New York, New York. Avenue Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people.Things to note about Avenue Therapeutics performance evaluation
Checking the ongoing alerts about Avenue Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Avenue Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Avenue Therapeutics generated a negative expected return over the last 90 days | |
| Avenue Therapeutics has high historical volatility and very poor performance | |
| Avenue Therapeutics has some characteristics of a very speculative penny stock | |
| Avenue Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (10.38 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Avenue Therapeutics currently holds about 890 K in cash with (9.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 25.0% of the company shares are held by company insiders |
- Analyzing Avenue Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Avenue Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Avenue Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Avenue Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Avenue Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Avenue Therapeutics' pink sheet. These opinions can provide insight into Avenue Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avenue Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Consideration for investing in Avenue Pink Sheet
If you are still planning to invest in Avenue Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Avenue Therapeutics' history and understand the potential risks before investing.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |